Jacob Anderson-Bialis is a co-founder of FertilityIQ, an online educational resource used by 4 million patients in over 55 countries and languages. He earned his master’s degree from Harvard University (top 5% in class) and his bachelor’s degree from Duke University (top 1% in class). He is a resident of New Zealand and the United States and is proficient in English and Russian.
Dr. Bormann is an Assistant Professor at Harvard Medical School. He is the Director of the Assisted Reproductive Technology (ART) Laboratory Massachusetts General Hospital. His research interests include using deep-learning, AI-technology to help individualize patient care and assist in clinical/laboratory decision making.
Dr. Capalbo received his Bachelor of Science degree in Biotechnology from University of Rome ‘La Sapienza’ and his Ph.D. magna cum laude in Human Genetics at the Catholic University of Sacred Heart of Rome in 2011. From 2008 to 2012 Dr. Capalbo has been working as a clinical embryologist, pioneering embryo biopsy approaches and applications. Since then, his research has focused on preimplantation genetic testing and on the development of novel molecular biology techniques to improve pregnancy and take-home baby rates in ART. His basic research has been focused on the mechanisms of aneuploidies in oocytes and preimplantation human embryos. He received several grants for innovative studies on these subjects. From 2012-2017 he was co-founder and Laboratory Director at GENETYX, the largest PGT program in Italy. From 2017 until July 2022, he has been working as Genomics Research Director at Igenomix, and as laboratory director for Igenomix Italy. He is currently coordinator of the ESHRE SIG in Reproductive Genetics, member of the genomics-working group of the Italian society of human genetics, and Chief Genomic Officer at Juno Genetics. He has published more than 100 peer-reviewed papers and book chapters and is currently Reviewer and Associated Editor for many Journals in the field of reproductive biology and genetics (New England Journal of Medicine, American Journal of Human Genetics, Human Reproduction Update, Human Reproduction, Fertility and Sterility, Reproductive BioMedicine Online, Journal of Assisted Reproduction and Genetics, Journal of Medical Genetics, Scientific Reports, PNAS).
Bart CJM Fauser, MD, PhD, FRCOG, is a Professor Em. of Reproductive Medicine, Gynaecologist, former Chair of the Department for Reproductive Medicine and Gynaecology and Head of the Division of Woman & Baby at the University of Utrecht and the University Medical Center Utrecht, The Netherlands.
He is also a Fellow ad Eundum of the Royal College of Obstetrics and Gynaecology (RCOG), Honorary member of European Society of Human Reproduction and Embryology (ESHRE), scientific director of the International Federation of Fertility Societies (IFFS), international member of the National Academy of Medicine (US), Past Editor-in-Chief of Reproductive Biomedicine Online (RBMO) and Human Reproduction Update (HRU), Editor of Fertility & Sterility Science, and Night in the order of the Netherlands Lion.
Bart previously acted as a member of the board of the Dutch Medical Research Counsel (ZonMW), chair of the World Health Organization (WHO) steering committee for infertility guidelines, Chair of the ESHRE SIG Reproductive Endocrinology, Fulbright post-doctoral scholar at the University of California, San Diego, Professor and Division director at the Erasmus University, Rotterdam (The Netherlands); and acted as visiting professor at Stanford University School of Medicine (California, USA), Free University of Brussels (Belgium), University of Siena (Italy), University of Southampton (UK), and the University of Adelaide (Australia).
His major research interests include the pathophysiology of human ovarian function (especially PCOS, and POI), ovarian stimulation, IVF and women’s health (including contraception, menopause and healthy aging). He has published ~ 500 peer-reviewed papers, edited 5 books, and contributed around 80 chapters to all leading textbooks in Reproductive Medicine. is one of the most cited (Hirsch factor ~120) authors in reproductive medicine worldwide, and his work has been widely covered in the national and international news media.
David is a Pioneer in human IVF. He is a Distinguished Professor in the School of BioSciences, University of Melbourne and the Scientific Director of Melbourne IVF.
He completed his PhD (1987) at the University of York, with Henry Leese. In 1988 he moved to Harvard Medical School to work with John Biggers, after which he moved to Monash, Australia, in 1989 to work with Alan Trounson. In 1997 became the Scientific Director of the Colorado Centre for Reproductive Medicine in Denver, where his work on human embryo culture conditions and blastocyst transfer revolutionised how human IVF is performed today.
His “Gardner Grading system” for the human embryo is used worldwide as the standard selection system in human IVF.
In 2007 he was appointed Professor and Chair of the Zoology Department at the University of Melbourne and promoted to the level of Distinguished Professor, School of BioSciences in 2018.
In 2017 he became the Scientific Director of Melbourne IVF.
In 2017 in recognition of his many significant contributions to reproductive sciences he was elected as a Fellow into the Australian Academy of Science (FAA) and further was the recipient of the Distinguished Researcher Award from the American Society of Reproductive Medicine.
In June 2022, he was awarded the Order of Australia (AM) (one of the highest civil honours in Australia) for his significant contributions to reproductive medicine.
He has published over 300 papers and chapters and has edited 16 books on IVF and embryology, culminating in over 33,000 citations.
Dr. Luca Gianaroli is specialist in Reproductive Medicine since the end of the Seventies. He is the Scientific Director of S.I.S.Me.R. (Italian Society for the Study of Reproductive Medicine) and he holds the position of Scientific Director of IIIRM SA in Lugano, Switzerland. He is also advisor of the Italian Ministry of Health for Medically Assisted Reproduction.
Dr. Gianaroli has always been an active member of several national and international scientific societies in which he has covered and currently covers roles of primary importance.
In 2009-2011, he served as Chairman of the European Society of Human Reproduction and Embryology (ESHRE).
In 2014 he was appointed as Fellow ad eundem of the Royal College of Obstetricians and Gynaecologists.
In 2017, he was one of the founders of the Fondazione PMA.Italia (PMA.Italia Foundation), of which he is currently the Vice-President. From 2016 to 2021 he served as coordinator of the Steering Committee of the ESHRE ART Centre Certification Program.
At present, he is the Director of Global Educational Programs of the International Federation of Fertility Societies (IFFS).
With reference to academic activities, throughout his professional career Dr. Gianaroli collaborated with several universities in Italy (Università degli Studi di Teramo, Università degli Studi di Modena e Reggio Emilia, Università degli Studi di Trieste, Università degli Studi di Roma Tor Vergata, Università di Bologna) and abroad (Leuven University in Belgium, Monash University in Australia and Geneva University in Switzerland). He served as Honorary Professor at the School of Biosciences of the University of Kent between 2014 and May 2022. In 2014 he obtained the Italian Abilitazione Scientifica Nazionale (National Scientific License) as Full Professor, which was renewed in 2020.
Dr. Gianaroli is author of more than 290 papers in international scientific journals and publisher or co-publisher of 9 books. As of the date of this biosketch his H-index is 80 (Google Scholar).
Linda C Giudice, MD, PhD is Distinguished Professor of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco. She is a biochemist and reproductive endocrinologist specializing in endometriosis, adenomyosis, ovulatory disorders and infertility. Her research focuses on multi-omics approaches to elucidate function and dysfunction of human endometrium in health and disease and environmental impacts on reproductive health. She has mentored >320 students, fellows and faculty, authored >370 peer-reviewed publications and is co-editor of 7 textbooks on women’s health, endocrinology, environmental health, endometrium, and endometriosis. She has received numerous awards acknowledging her contributions to science, medicine, and mentoring. Dr. Giudice is Past-President of the American Society for Reproductive Medicine, Society for Reproductive Endocdrinology and Infertility, World Endometriosis Society, and International Federation of Fertility Societies. She is immediate past Chair of the FIGO Committee on Climate Change and Toxic Environmental Expsoures and is an elected member of the U.S. National Academy of Medicine and the U.S. National Academy of Inventors.
Professor Ariel Hourvitz is the director of the IVF unit of the Shamir (Assaf Harofeh) Medical Center and Principal Investigator at the Reproduction Laboratory, at the Chaim Sheba Medical Center, Tel Hashomer.
He is full professor in Obstetrics and Gynecology and endows of “The Alan and Ada Selwyn Chair in Clinical Infertility Research and Molecular Medicine” at the School of Medicine, Tel-Aviv University, Israel.
He is also co-founder and CMO of FertilAI, LTD.
Professor Hourvitz graduated the Sackler School of Medicine, Tel-Aviv University in 1985 and accomplished his specialization in Obstetrics and Gynecology in Tel-Hashomer. He obtained a Master in Obstetrics and Gynecology from the Sackler School of Medicine, and a Master in Health Administration Cum Laude, from the Faculty of Management, Tel Aviv University. He has done a research postdoctoral fellowship in reproductive sciences, at the department of Obstetrics and Gynecology, University of Utah, and a visiting Fellowship in reproductive sciences at the CRMI, Weill Medical College at the Cornell University, and New York Presbyterian Hospital in New-York.
Professor Hourvitz research interests include basic research on ovarian physiology, folliculogenesis and characterization of the human ovulatory cascade. In the clinical research he focused on agonist triggering, ovarian stimulation protocols, ovulation, IVM and IVA. Recently, he was involved in development of ovarian stimulation protocols based on Artificial Intelligence (AI).
He has been invited to speak in national and international meetings, and along with his colleagues, has published over 100 peer-reviewed articles in international journals and books.
Dr. Kelle Moley is a career physician-scientist obstetrician/gynecologist with a 35+-year history of basic, translational and clinical research into reproductive health issues including male and female infertility, maternal health, contraception, obesity in pregnancy, preterm birth, sexually transmitted infections and endometriosis.
Kelle spent 3 decades in academia at Washington University in St. Louis most recently as the James P. Crane Professor of Obstetrics & Gynecology, Vice Chair and Chief of the Division of Basic & Translational Research. Her collaborative research (published in over 150 peer-reviewed articles) led to an international reputation along with numerous scholarly honors, including election to the National Academy of Medicine in 2014. She left academia in 2018 to become the Chief Scientific Officer and Senior Vice President of the March of Dimes where she facilitated a cooperative team of 6 Prematurity Research Centers in the US and UK at Stanford University, University of Chicago, Washington University in St. Louis, University of Pennsylvania and Imperial College in London. From there she went to the Bill and Melinda Gates Foundation where she assumed the role of Deputy Director of Reproductive Health Technologies, a new division within Global Health and created a strategic portfolio to tackle global problems of HPV and cervical cancer, vaginal dysbiosis otherwise known as Bacterial Vaginosis, non-hormonal contraceptives, novel menstrual products and STI vaccines.
Just recently on Sept 1, 2022, Kelle joined Ferring Pharmaceuticals as Global Vice President of Research and Development in Reproductive Medicine and Maternal Health. In her current role she leads a team to drive innovation in women’s health therapeutics and technologies with the goal of achieving better health outcomes for women at every stage of the reproductive journey. With extensive expertise in academic discovery science, clinical medicine, the non-profit space of maternal health, and the role of philanthropic foundation contribution to this area of unmet need, and now her newest adventure in the pharma industry, Kelle strives to change the global healthcare paradigm for sexual and reproductive health in women and girls, empowering them to pursue their life aspirations.
Inmaculada Moreno is a Senior Principal Investigator at the Carlos Simon Foundation for Research in Women’s Health, where she develops basic and translational research projects regarding the impact of the microbiome in human reproduction.
Her main scientific interest is understanding how microorganisms impact embryo implantation, pregnancy success, and women’s health in general.
She demonstrated the existence of the endometrial microbiota and reported an association between the microbiome and reproductive outcomes in infertile patients. Furthermore, she studied the functional impact of bacteria present in the endometrium in reproductive failure and, for the first time, during early successful pregnancy. Her research also focuses on improving diagnostic methods for chronic endometritis, a subclinical infection of the endometrium with adverse effects on fertility, and searching for potential probiotics for endometrial health.
Dr. Moreno has more than 15 years of professional experience in molecular microbiology and biochemistry. From 2015 to 2018, she collaborated with the Reproductive and Stem Cell Biology laboratory at Stanford University School of Medicine as a Visiting Scholar. She has been productive in basic and clinical research with over 40 published papers in peer-reviewed journals with an accumulated impact factor of 279.94. Her papers have been cited 1,279 times with an average of 30.45 citations/paper, and she has an H-Index of 21. She has published 5 invited book chapters, including the Encyclopedia of Reproduction, and has participated in over 100 international conferences.
Dr. Craig Niederberger is Clarence C. Saelhof Professor and Head of the Department of Urology in the College of Medicine at the University of Illinois at Chicago, and holds a joint appointment as Professor in the Department of Bioengineering in the College of Engineering. He co-founded NexHand as Chief Techology Officer and leads the multidisciplinary UR*Lab in the Innovation Center at the University of Illinois at Chicago. He was Co-Editor in Chief of Fertility and Sterility and a prior section editor for the Journal of Urology. He is a primary editor of the fourth and upcoming fifth editions of Infertility in the Male. He served as general program chair for the American Society for Reproductive Medicine’s annual meeting in Atlanta in 2009 and has served as president of the Society for the Study of Male Reproduction within the American Urological Association and as president of the Society for Male Reproduction and Urology within the American Society for Reproductive Medicine.
Dr O’Neill(MSc, PhD) is CEO and Founder of Hertility, an award-winning digital health company shaping the future of reproductive healthcare by pioneering unique diagnostic testing that provides data-driven and advanced insights into reproductive health, fertility decline and the onset of menopause. Hertility was featured in Forbes as one of ten companies with world-changing potential.
Dr Helen O’Neill is a Tenured Lecturer in Reproductive and Molecular Genetics at the Institute for Women’s Health, University College London. She has an MSc in Prenatal Genetics and Fetal Medicine, a PhD in Stem Cell Biology and Developmental Genetics from UCL and has spent the last 15 years researching genetics, fertility and women’s health. As a thought leader in reproductive science, she is a TedX speaker, has been interviewed frequently on the BBC, BBC World News, Sky News, the Guardian and was awarded in the Top Twenty Women in Data, 2019 as well as Top 50 Women in European Tech by the Financial Times.
Dr. Orwig is a Professor of Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh School of Medicine. He is also the director of the Fertility Preservation Program and the Center for Reproduction and Transplantation at Magee-Womens Hospital of UPMC. Research in the Orwig laboratory focuses on stem cells, germ lineage development, fertility and infertility. Our progress investigating reproductive function in fertile individuals provides a basis for understanding the mechanisms of infertility caused by disease, medical treatments, genetic defects or aging. Infertility impacts one in seven couples in the United States and can have a devastating impact on relationships, emotional well-being and overall health. The Orwig lab is ideally located in Magee-Womens Research Institute and Magee-Womens Hospital of the University of Pittsburgh and is committed to translating lab bench discoveries to the clinic for diagnosis, prevention and treatment of infertility.
Dr. Ravel received his Ph.D. degree from the University of Maryland College Park in Environmental Molecular Microbiology and Ecology and performed his postdoctoral training as a Ruth L. Kirschstein National Research fellow in the Chemistry Department at The Johns Hopkins University in Baltimore, MD working on the chemistry and bioinformatics natural products. He joined the Institute for Genome Sciences at the University of Maryland School of Medicine in 2007 as an Associate Professor. Previously, from 2002 to 2007 he was an Assistant Investigator at The Institute for Genomic Research (TIGR) in Rockville, MD, the pioneering institute where the firsts microbial genome was sequenced.
Dr. Jacques Ravel is a Professor in the Department of Microbiology and Immunology and the Acting Director at the Institute for Genome Sciences, University of Maryland School of Medicine in Baltimore, MD. Over the past 18 years he has developed a research program focused on applying modern genomics technologies and ecological principles to characterize the role and dynamics of the vaginal microbiome in women’s health. He uses clinical genomics and systems biology approaches to develop improved strategy to manage gynecological and obstetrics conditions. He has published over 300 peer-reviewed publications. He is the co-Director (PI) of the NIH funded Collaborative Research Center on Human 3D Biomimetics Cervicovaginal Models for Sexually Transmitted Infections which
aims to develop an innovative biomimetic model of the lower reproductive tract to study aspects of the sexually transmitted infections (STIs), chlamydia and gonorrhea, that are not achievable in humans or with current animal or cell models. The program specifically uses systems biology approaches to examine the triangular relationship between human genetic variation, sexually transmitted infections and infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae, and the function of the vaginal microbiome. Further, his laboratory studies the role of the vaginal microbiota in bacterial vaginosis, pregnancy and prematurity, as well as the health of neonates. His foundational research is currently being translated by developing novel live microbiome-based live biotherapeutic formulations targeted to restore vaginal health, treat conditions such as bacterial vaginosis and urinary tract infections. His work earned him to be elected to Fellowship of the American Academy of Microbiology (AAM) in 2012, and in 2015, he was awarded the Blaise Pascal International Research Chair and spend two years at the Institut Pasteur in Paris. He is the founder and Editor in Chief of the journal Microbiome (www.microbiomejournal.com), which has achieved an impact factor of 19.9 in the 10 years since its creation, and as a fellow of the AAM, he is an Associate Editor for the journal mBio.
Prof. Laura Rienzi Adjunct Professor of Biotechnology in Assisted Reproduction, University of Urbino, Italy Director of the Scientific Executive Committee of GeneraLife and co-founder of Genera Senior Clinical Embryologist
With 30 years’ experience in human assisted reproduction technologies, pre-implantation genetic testing and cryopreservation of human oocytes, sperm and embryos, Laura Rienzi is the Director of the Scientific Executive Committee of the GeneraLife network of IVF clinics in Europe.
Laura obtained her degree in Biology magna cum laude at the University of Rome “La Sapienza”, University of Rome, a Master degree and a course specialization in Reproductive Medicine at the University of Padua. Since 2016, she is Adjunct Professor of Biotechnology in Assisted Reproduction at the Faculty of Biology, University of Urbino, Italy. She has authored >200 articles (Scopus Index 52), reviews and book chapters, she has also been invited to speak in more than 300 national and international scientific meetings and has won several awards regarding fertility investigation and innovation.
In 2008 she founded together with Dr. Filippo Maria Ubaldi the Genera IVF centers, with 4 different locations in Italy, where she is Laboratory Director. In 2020, she was actively involved in the creation of GeneraLife, a network of >30 clinics in 5 different countries in Europe: the name GeneraLife was inspired by the group she founded 12 years before.
Trained in Science and Embryology in the University of Valencia, Spain, Dr Carmen Rubio specialized in cytogenetic studies in human reproduction, partly in the University of Barcelona. She completed her PhD in the field of Reproductive Genetics and post-doctoral research included research in male and female meiosis at the laboratory of Drs. Patricia Hunt and Terry Hassold (Washington State University, USA). She has published more than 100 papers in the main peer-reviewed specialist journals in the field, books chapters as well as numerous lectures at conferences worldwide. She is Board member of the PGDIS society, and the PGT Consortium working group, under the auspices of ESHRE. Currently she is the head of the Research & Development department at Igenomix (Vitrolife group). Her main research interests are non-invasive approaches of embryo aneuploidy and understanding the origin of cell-free DNA in the culture medium.
Dr. Denny Sakkas received his undergraduate training at the University of Melbourne, Australia and received his Doctorate of Philosophy at Monash University, Melbourne, Australia. He has been the Laboratory Director of IVF units in Europe and the USA and has extensive experience in clinical IVF and reproductive research. Dr Sakkas is currently Chief Scientific Officer at Boston IVF and remains as an Associate Professor at the Department of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine.
Carlos Simon is Professor of Ob/Gyn at the University of Valencia (Spain), Senior Lecturer PT, BIDMC Harvard University, USA, and Adjunct Clinical Professor at Baylor College of Medicine, USA.
His main clinical and scientific interest is in understanding human embryonic implantation, a critical process to the survival of the species, considering the embryo, the maternal endometrium, and their cross-communication as crucial elements.
He discovered a transcriptomic signature of human endometrial receptivity using microarray technology, which was confirmed by single-cell RNA sequencing. Clinical translation of this research resulted in a patent for the creation of the endometrial receptivity analysis (ERA) to diagnose the personalized window of implantation in infertile patients. He provided evidence of a decidualization defect in the endometrium of women with severe preeclampsia, a pathology detectable at the time of delivery and persisting for years, also discovering the footprint encoding this defect. Next, he demonstrated that the human uterine cavity is not sterile, by reporting the existence of the endometrial microbiome and its functional implications in pregnancy. He also discovered the existence and provided functional proof of concept for the existence of human endometrial stem cells. Today, these findings are being translated to the first advanced cellular therapy for Asherman’s Syndrome (EudraCT Number: 2016-003975-23). For the human embryo, he created a prediction model for aneuploidy in early embryo development revealed by single-cell analysis, deciphered the clinical impact of embryo mosaicism, and discovered the origin and composition of human embryo cell-free DNA and its clinical impact. His team derived, characterized, and registered ten human embryonic stem cell lines in the Spanish National Stem Cell Bank. His pioneering work in this field made possible the creation of the Valencia Node of the Spanish Stem Cell Bank in 2004. Finally, he addressed cross-communication between the maternal endometrium and the embryo, discovering that maternal microRNAs might act as a transcriptomic modifier of the pre-implantation embryo.
His commitment to excellence in research has been demonstrated by the publication of over 500 papers (PubMed) in peer-reviewed journals with an accumulated impact factor of 3,826.24. His papers have received over 46,000 citations, and he has a Google Scholar H-index of 123. He has edited 21 books in English, Spanish, and Portuguese and supervised 38 Ph.D. theses. Several scientific societies and institutions have awarded his research, including the Rey Jaime I Medical Research Award 2011, the ASRM Distinguished Research Award in 2016, and the Lilly Foundation Biomedical Research Award in 2021.
His commitment to excellence in clinical care has been demonstrated by his instrumental role as a clinician and scientific director in establishing IVI’s clinical practice and research program from 1994 to 2018 (www.ivirma.es). As an inventor and entrepreneur, his research has generated 17 patent applications that enabled the creation of Igenomix S.L. in 2011, in which he was a founder and the chief science officer (CSO), leading a scientific/medical team of 120 Ph.D. students worldwide until it was acquired by Vitrolife in 2021, a biotech company devoted to precision medicine in reproductive health through advanced reproductive genetic diagnoses with an international footprint on all continents.
Felipe Vilella, a Ph.D. in molecular biology, is the consolidated group leader of the Maternal Fetal Crosstalk Laboratory at INCLIVA/Carlos Simon Foundation. He performed two post-doctoral positions, one in the Clinical Science Centre of the MRC in London (UK) and the other in the Centro de Investigaciones Principe Felipe in Valencia (Spain). He was a visiting researcher for five years at Stanford University (USA) and two years at Harvard University (USA).
His main scientific interest focuses on understanding the communication mechanisms occurring between the mother and the embryo and elucidating how the mother can genetically modify the preimplantation embryo.
His research was the first to demonstrate the transmission of genetic information from the mother to the preimplantation embryo, demonstrating that the mother can modify the embryo transcriptomically and/or epigenetically, regardless of its genetic background. He studied the effect of microRNAs and mitochondrial DNA secreted by endometrial cells on the embryo. He also focuses on understanding the implantation process, elucidating how endometrial cells communicate with each other at the single-cell level.
He has published 44 papers in peer-reviewed journals with an accumulated impact factor of 399.35. His papers have been cited 2,267 times with an average of 56.68 citations/paper. He has an H-Index of 24, has published 12 book chapters, and has directed 6 Ph.D. theses. He has participated in over 16 international projects, being an independent principal investigator in 11. He has participated as an invited speaker at over 80 international conferences.
Founder and CEO of MIM Solutions, a Polish IT company specializing in innovative AI solutions for the medical sector. Piotr Wygocki is an innovator and scientist. A graduate of the University of Warsaw, a PhD in computer science with a double master’s degree in computer science and mathematics. Assistant professor at the University of Warsaw.
This site place cookies on your device for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.